Paradigm Biopharmaceuticals Ltd.ASX: PAR

PAR Reports Successful Primary Endpoint in Phase 2 Trial

Oct 4, 2022 at 2:33 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment